Cellares Corporation’s CEO Fabian Gerlinghaus talks about the limitations in cell therapy production and its Cell Shuttle technology.

Dan Stanton, Managing editor

May 11, 2021

1 Min Read
Podcast: On board the Cell Shuttle with Cellares
Fabian Gerlingahaus, CEO of Cellares, spoke on the BioProcess Insider Expression Platform podcast

Cellares Corporation’s CEO Fabian Gerlinghaus talks about the current limitations in cell therapy production and how, with $82 million in hand, its Cell Shuttle technology could resolve these.

Tech firm Cellares Corporation is looking to advance development of its cell therapy manufacturing platform, the Cell Shuttle.

cellares-ceo-300x172.jpg

Fabian Gerlingahaus, CEO of Cellares, spoke on the BioProcess Insider Expression Platform podcast

Having raised $82 million in its latest funding round, co-founder and CEO Fabian Gerlinghaus spoke about how the Cell Shuttles’ scalable, modular, and automated nature could be a gamechanger in the burgeoning space on the latest edition of the BioProcess Insider Expression Platform.

Listen to it below, or on iTunes, Google Podcasts, Spotify, or wherever you get your podcasts.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.


Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.


From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like